Evaluation of ER and Ki-67 proliferation index as prognostic factors for survival following neoadjuvant chemotherapy with doxorubicin/docetaxel for locally advanced breast cancer
Evaluation of ER and Ki-67 proliferation index as prognostic factors for survival following neoadjuvant chemotherapy with doxorubicin/docetaxel for locally advanced breast cancer
复制标题
DOI：
10.1007/s00280-007-0506-8
复制
发表时间：
2008-04-01
影响因子：
3
通讯作者：
Yang, J. H.
中科院分区：
文献类型：
--
作者：
Lee, J.;Im, Y. H.;Yang, J. H.
背景这项研究的目的是确定可靠的预测生物学标记物的治疗结果后，新辅助阿霉素/多西他赛（AT）化疗在局部晚期乳腺癌patients.Materials和方法本研究是一项II期研究AT新辅助化疗在局部晚期乳腺癌患者。患者接受50 mg/m2多柔比星静脉注射（IV）15分钟，随后多西他赛75 mg/m2静脉输注1小时，每3周重复一次，共3个周期。在最后一个化疗周期后3-4周内进行手术。我们分析了治疗前和治疗后的ER，PgR，HER-2，Ki-67增殖指数和p53的表达水平，并检查标记物和临床参数与治疗反应，总生存率和无复发生存率以下新辅助治疗的相关性。对生存率有不利影响的有意义的参数是治疗后ER（-）状态（P = 0.013）和治疗后Ki-67指数高于1.0%（P = 0.013）。在多变量水平，治疗后Ki-67增殖指数
Background The aim of the study was to identify reliable predictive biological markers for treatment outcome following neoadjuvant adriamycin/docetaxel (AT) chemotherapy in locally advanced breast cancer patients.Materials and methods This study was a phase II study on AT neoadjuvant chemotherapy in locally advanced breast cancer patients. Patients received 50 mg/m(2) of doxorubicin intravenously (IV) over 15 min followed by docetaxel 75 mg/m(2) infused over 1 h, repeated every 3 weeks for three cycles. Surgery was performed within 3-4 weeks following the last cycle of chemotherapy. We analyzed the pre-treatment and post-treatment expression levels of ER, PgR, HER-2, Ki-67 proliferation index, and p53 and examined the correlation between the markers and clinical parameters with treatment response, overall survival and relapse-free survival following neoadjuvant treatment.Results From July 2001 to September 2004, 61 patients were enrolled. The meaningful parameters adversely influencing survival were post-treatment ER(-) status (P = 0.013) and post-treatment Ki-67 index above 1.0% (P = 0.013). At the multivariate level, the post-treatment Ki-67 proliferation index